This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anawalt, B. D. Articles by Matsumoto, A. M. Search for Related Content PubMed PubMed Citation Articles by Anawalt, B. D. Articles by Matsumoto, A. M.

Intramuscular Testosterone Enanthate Plus Very Low Dosage Oral Levonorgestrel Suppresses Spermatogenesis Without Causing Weight Gain in Normal Young Men: A Randomized Clinical Trial

BRADLEY D. ANAWALT^*,

KAREN L. HERBST

ALVIN M. MATSUMOTO^*,,

From the ^* Department of Medicine, Geriatric Research, Education and Clinical Center, University of Washington School of Medicine, Seattle, Washington; the Veterans Affairs Puget Sound Health Care System; and the Department of Medicine, Charles R Drew University, Los Angeles, California.

Correspondence to: Dr Bradley D. Anawalt, VA Puget Sound S-111-CHF, 1660 S Columbian Way, Seattle, WA 98108 (e-mail: bradley.anawalt{at}med.va.gov).

The development of a safe, well-tolerated, effective, and reversible male hormonal contraceptive would be a major clinical advance for couples planning their family size and for control of population growth. High-dosage parenteral testosterone (T) esters alone or in combination with a progestogen (eg, depot medroxyprogesterone) have been shown to confer effective and reversible male contraception in clinical trials, but these regimens are associated with weight gain and suppression of serum high-density lipoprotein cholesterol (HDL) levels. We have previously demonstrated that intramuscular T enanthate 100 mg weekly plus oral levonorgestrel (LNG) 125, 250, or 500 µg daily suppresses spermatogenesis to levels associated with effective contraception, but there is a LNG-dosage-dependent effect of weight gain and HDL suppression. We hypothesized that intramuscular T enanthate 100 mg weekly plus a very low dosage of oral LNG would effectively suppress spermatogenesis in normal men without inducing weight gain or HDL suppression. We conducted a randomized trial comparing 6 months of intramuscular T enanthate (100 mg weekly) plus 31.25 µg of oral LNG daily (T+LNG 31; n = 20) or 62.5 µg of oral LNG daily (T+LNG 62; n = 21). The 2 regimens were equally effective in suppressing spermatogenesis to azoospermia, fewer than 1 million sperm/mL and fewer than 3 million sperm/mL (T+LNG 31 [60%, 85%, and 90%] vs T+LNG 62 [62%, 91%, and 95%] for azoospermia, fewer than 1 million and fewer than 3 million, respectively; P = NS). The T+LNG 31 group did not gain weight (0.25 ± 1.08 kg; P = NS compared with baseline), but the T+LNG 62 group gained 2.5 ± 0.77 kg (P < .05 compared with baseline). Serum HDL cholesterol levels declined significantly in both groups (percentage decline month 6 of treatment vs baseline: 12.0% ± 2.6% and 15.1% ± 3.0%; P < .05 for T+LNG 31 and 62 respectively). Serum low-density lipoprotein cholesterol levels also declined in both groups (percentage decline month 6 of treatment vs baseline: 6.9 ± 3.9 and 6.0% ± 4.1%; P < .05 for T+LNG 31 and P = NS for T+LNG 62). There were no clinically significant adverse events or significant changes in hematology or chemistry profiles in either group during the study. We conclude that 1) intramuscular T plus oral LNG has a very potent synergistic effect in suppressing spermatogenesis at LNG dosages equal to or lower than dosages used in common female oral contraceptive regimens and 2) large, long-term contraceptive efficacy trials should be conducted with a variety of androgen-progestogen combinations including long-acting T formulations such as depot T pellets or intramuscular T undecanoate plus depot LNG or very low dosage oral LNG.

     Key words: Contraception, gonadotropins, azoospermia, oligospermia, oligoazoospermia, free testosterone

This article has been cited by other articles:

				S. T. Page, J. K. Amory, and W. J. Bremner Advances in Male Contraception Endocr. Rev., June 1, 2008; 29(4): 465 - 493. [Abstract] [Full Text] [PDF]

				P. Y. Liu, R. S. Swerdloff, B. D. Anawalt, R. A. Anderson, W. J. Bremner, J. Elliesen, Y.-Q. Gu, W. M. Kersemaekers, Robert. I. McLachlan, M. C. Meriggiola, et al. Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1774 - 1783. [Abstract] [Full Text] [PDF]

				J. K. Amory, S. T. Page, B. D. Anawalt, A. D. Coviello, A. M. Matsumoto, and W. J. Bremner Elevated End-of-Treatment Serum INSL3 Is Associated With Failure to Completely Suppress Spermatogenesis in Men Receiving Male Hormonal Contraception J Androl, July 1, 2007; 28(4): 548 - 554. [Abstract] [Full Text] [PDF]

				S. T. Page, J. K. Amory, B. D. Anawalt, M. S. Irwig, A. T. Brockenbrough, A. M. Matsumoto, and W. J. Bremner Testosterone Gel Combined with Depomedroxyprogesterone Acetate Is an Effective Male Hormonal Contraceptive Regimen and Is Not Enhanced by the Addition of a GnRH Antagonist J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4374 - 4380. [Abstract] [Full Text] [PDF]

				B. J. Attardi, S. A. Hild, and J. R. Reel Dimethandrolone Undecanoate: A New Potent Orally Active Androgen with Progestational Activity Endocrinology, June 1, 2006; 147(6): 3016 - 3026. [Abstract] [Full Text] [PDF]

				D. S. JOHNSTON, J. WOOTERS, G. S. KOPF, Y. QIU, and K. P. ROBERTS Analysis of the Human Sperm Proteome Ann. N.Y. Acad. Sci., December 1, 2005; 1061(1): 190 - 202. [Abstract] [Full Text] [PDF]